The $170 million up-front that Abbott Laboratories Inc. ponied up for PanGenetics BV's Phase I PG110 anti-nerve growth factor antibody would rank as the largest down payment ever for a Phase I project. But even though at first glance the mid-November deal resembles an alliance, it is in fact the acquisition of part of PanGenetics itself, and reveals founding investor Index Ventures' intriguing asset-focused strategy.
PanGenetics, explains chairman and Index partner Francesco De Rubertis, PhD, is not one biotech company, but two single-asset companies under...







